EC Orthopaedics

Nerve Growth Factor (NGF), a neurotrophin originally identified for its role in the development and survival of sensory and sympathetic neurons, has emerged as a key modulator in pain perception and inflammatory processes. Growing evidence highlights its involvement in chronic inflammatory diseases, particularly osteoarthritis (OA), rheumatoid arthritis (RA), and other pain-associated musculoskeletal conditions.The role of NGF in joint degeneration extends beyond its well-established involvement in pain. NGF acts as a multifaceted mediator in the pathophysiology of osteoarthritis by influencing chondrocyte catabolism, promoting aberrant neurovascular remodelling and facilitating synovial fibrosis. These findings suggest that targeting NGF could provide symptomatic relief and disease modification, although further research is required to confirm long-term structural outcomes.

 Keywords: Nerve Growth Factor; Pain; Osteoarticular; Inflammation

1. Aloe L and Tuveri MA. “Nerve growth factor and autoimmune rheumatic diseases”. Clinical and Experimental Rheumatology 4 (1997): 433-438.
2. Aloe L., et al. “The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases”. Allergy9 (1997): 883-894.
3. Kanda N and Watanabe S. “Regulatory roles of sex hormones in cutaneous biology and immunology”. Journal of Dermatological Science 1 (2005): 1-7.
4. Toyomoto M., et al. “Prostaglandins are powerful inducers of NGF and BDNF production in mouse astrocyte cultures”. FEBS Letters 1-3 (2004): 211-215.
5. Falcini F., et al. “Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis”. Annals of the Rheumatic Diseases 10 (1996): 745-748.
6. Kritas SK., et al. “Nerve growth factor interactions with mast cells”. International Journal of Immunopathology and Pharmacology 1 (2014): 15-19.
7. Burnstock G. “Cotransmission in the autonomic nervous system”. Handbook of Clinical Neurology 117 (2013): 23-35.
8. Sung CP., et al. “Neuropeptide Y upregulates the adhesiveness of human endothelial cells for leukocytes”. Circulation Research 1 (1991): 314-318.
9. Pongratz G and Straub RH. “The sympathetic nervous response in inflammation”. Arthritis Research and Therapy 6 (2014): 504.
10. Minnone G., et al. “NGF and its receptors in the regulation of inflammatory response”. International Journal of Molecular Sciences 5 (2017): 1028.
11. Jiajia Xu., et al. “NGF-p75 signaling coordinates skeletal cell migration during bone repair”. Science Advances 11 (2022): eabl5716.
12. Zhao L., et al. “Nerve growth factor receptor limits inflammation to promote remodeling and repair of osteoarthritic joints”. Nature Communications 1 (2024): 3225.
13. Colardo M., et al. “NGF modulates cholesterol metabolism and stimulates ApoE secretion in glial cells conferring neuroprotection against oxidative stress”. International Journal of Molecular Sciences 9 (2022): 4842.
14. Aso K., et al. “Associations of symptomatic knee osteoarthritis with histopathologic features in subchondral bone”. Arthritis and Rheumatology 6 (2019): 916-924.
15. Aso K., et al. “Increased nerve growth factor expression and osteoclast density are associated with subchondral bone marrow lesions in osteoarthritic knees”. Osteoarthritis and Cartilage Open 3 (2024): 100504.
16. Zhu S., et al. “Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain”. Journal of Clinical Investigation 3 (2019): 1076-1093.
17. Seidel MF., et al. “Localization of nerve growth factor expression to structurally damaged cartilaginous tissues in human lumbar facet joint osteoarthritis”. Frontiers in Immunology 13 (2022): 783076.
18. Dietz BW., et al. “Targeting nerve growth factor for pain management in osteoarthritis-clinical efficacy and safety”. Rheumatic Disease Clinics of North America 2 (2021): 181-195.
19. Charles Birbara., et al. “Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis”. Journal of Pain Research 11 (2018): 151-164.
20. Paula Dakin., et al. “The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial”. Arthritis and Rheumatology 11 (2019): 1824-1834.
21. Ekman EF., et al. “Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen”. Journal of Rheumatology 11 (2014): 2249-2259.
22. Devi Rani Sagar., et al. “Osteoprotegerin reduces the development of pain behaviour and joint pathology in a model of osteoarthritis”. Annals of the Rheumatic Diseases 8 (2014): 1558-1565.
23. Wang H., et al. “Osteoclasts and osteoarthritis: Novel intervention targets and therapeutic potentials during aging”. Aging Cell4 (2024): e14092.
24. Chen W., et al. “Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues”. Acta Biochimica et Biophysica Sinica (Shanghai) 4 (2024): 499-512.
25. Akoum J., et al. “Netrin-1 secreted by human osteoarthritic articular chondrocytes promotes angiogenesis in vitro”. Cartilage 4 (2022): 94-104.
26. Nencini S., et al. “Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain”. Molecular Pain 13 (2017): 1744806917697011.
27. Eitner A., et al. “Mechanisms of osteoarthritic pain. studies in humans and experimental models”. Frontiers in Molecular Neuroscience 10 (2017): 349.
28. G R Lewin., et al. “Peripheral and central mechanisms of NGF-induced hyperalgesia”. European Journal of Neuroscience 12 (1994): 1903-1912.
29. Ivanusic JJ. “Molecular mechanisms that contribute to bone marrow pain”. Frontiers in Neurology 8 (2017): 458.